Ambuja Cement, Nestle India and Veritas to announce December quarter results today.
In Q3, the company has witnessed stronger growth than anticipated in the US, Emerging Markets and RoW.
Nifty Metal index soars 4%; Tata Steel, SAIL rally; ITC jumps to 7-week high as no tobacco tax relieves investors; Sun Pharma hits new 52-week high post Q3 results; Govt brings cryptos under tax net
The management said the company achieved a sustained momentum and good growth across businesses; despite rising costs, achieved higher profitability.
Adani Ports, Indian Hotels and Tech Mahindra are some of the prominent companies to announce results today.
In Q3, the revenue from specialty products came in at $183 million, up 21 per cent YoY
Large part of today's rally in the headline indices was led by IT stocks such Tech M, Wipro, Infosys and HCL Tech; financials such as Bajaj twins and SBI, and index heavyweights RIL
Total revenue from operations rose to Rs 9,863 cr in the third quarter as compared to Rs 8,836.7 cr in the same period of previous fiscal
In Q3FY22, Taro's EBITDA margins improved 108 bps year-on-year (YoY) to 31.3 per cent mainly due to better gross margins.
This launch is an important milestone for the drugmaker as it expands its ophthalmics portfolio into Canada, the firm said
Major stocks have broken out on upside, any trigger in Budget 2022 could see sharp up move
The better traction in the specialty segment and improvement in domestic business to drive the margin expansion in Q3.
Anti-covid drug approval, new facility are the near term triggers for the pharma firm's stock
Sun Pharma, Cipla, Natco, Dr Reddy's, Torrent Pharma, Aurobindo Pharma and Strides have launched a generic version of Molnupiravir in India post approval for emergency use authorisation from DCGI
Textiles shares shall be in limelight as the government has released the operational guidelines for the production-linked incentive (PLI) scheme
Sun Pharma is the fourth largest specialty generic pharmaceutical company in the world
Business Standard brings you the top headlines on Tuesday
Biomodifying will also receive a percentage of payments received for sublicenses of the licensed IP
Sun Pharmaceutical Industries said it is gearing up to introduce Merck Sharp Dohme and Ridgeback's molnupiravir under the brand name Molxvir in India
According to USFDA, the Mumbai-based drug maker is recalling the affected lot due to "failed moisture limits."